Pramlintide vs Tirzepatide
A side-by-side research comparison of Pramlintide and Tirzepatide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Pramlintide | Tirzepatide |
|---|---|---|
| Full name | Pramlintide (Symlin) | Tirzepatide (Dual GIP/GLP-1 Receptor Agonist) |
| Category | Weight Management | Weight Management |
| Status | FDA Approved | FDA Approved |
| Mechanism | Mimics amylin by activating amylin receptors, which slows gastric emptying, suppresses inappropriate glucagon secretion after meals, and increases satiety - complementing insulin's effects. | Activates both GIP and GLP-1 receptors simultaneously for synergistic effects on insulin secretion, appetite reduction, and fat metabolism. GIP activation enhances fat oxidation and energy expenditure. |
| Molecular weight | 3949.4 Da | 4,814 Da |
| Half-life | ~48 minutes | 5 days (120 hours) |
| Bioavailability | Subcutaneous injection | High (SubQ ~80%) |
| Typical dose | 15-120 mcg before meals | 2.5 mg → titrate up to 15 mg |
| Frequency | Before major meals | Once weekly |
| Route | Subcutaneous injection | Subcutaneous injection |
Pramlintide reported benefits
- Appetite suppression and satiety
- Slows gastric emptying
- Improves post-meal glucose control
- Modest weight loss
Tirzepatide reported benefits
- Superior weight loss (20-25%)
- Excellent glycemic control
- Reduced triglycerides
- Lower blood pressure
- Improved insulin sensitivity
- Potential MASH benefits
Related comparisons
Research and educational reference only. Not medical advice.